Israel’s Redhill Biopharma announced success in Phase III trials of RHB-102 – a once-a-day pill for the prevention of nausea in cancer patients. Redhill now plans to apply to the US Food and Drug Administration for a pre-New Drug Application (NDA) hearing for marketing approval for RHB-102.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000741764&fid=1725